Project ENVISAGE TAVI-AF – Edoxaban vs. Standard of Care and their effects on clinical inpatients having undergone…

Basic data

Acronym:
ENVISAGE TAVI-AF
Title:
Edoxaban vs. Standard of Care and their effects on clinical inpatients having undergone transcatheter aortic valve implantation - in atrial fibrillation
Duration:
20/07/2017 to 31/12/2022
Abstract / short description:
Study design: This is a multinational, multicenter, prospective,randomized, open-label study with blinded evaluation of endpoints (PROBE) parallel group study comparing Edoxaban with VKA in subjects with AF having undergone TAVI. Critical events will be adjudicated by an independent Clinical Event Committee (CEC). An independent Data and Safety Monitoring Board (DSMB) is responsible for monitoring safety during the study.
Indication Under Investigation: Use of Edoxaban in patients with atrial fibrillation (AF) and indication to chronic oral anticoagulation (OAC) after transcatheter aortic valve implantation (TAVI)
Co-Primary objectives: To assess the effect of Edoxaban versus vitamin K antagonist (VKA) on net adverse clinical events (NACE), i.e., the composite of all-cause death, myocardial infarction (MI), ischemic stroke,
systemic thromboembolism (SEE), valve thrombosis, and major bleeding (International Society on Thrombosis and Haemostasis [ISTH] definition).
Secondary objectives: To compare Edoxaban with VKA with regard to defined efficacy and safety endpoints.
Keywords:
Neue orale Antikoagulantien
TAVI
atrial fibrillation
Vorhofflimmern
Edoxaban
Herzklappenersatz

Involved staff

Managers

Department of Internal Medicine
Hospitals and clinical institutes, Faculty of Medicine

Contact persons

Faculty of Medicine
University of Tübingen

Local organizational units

Internal Medicine Department III
Department of Internal Medicine
Hospitals and clinical institutes, Faculty of Medicine

Funders

Parsippany, New Jersey, United States of America
Help

will be deleted permanently. This cannot be undone.